Ischemic Stroke Clinical Trial
Official title:
Improve Acute Reperfusion Treatment Quality for Stroke in China
Verified date | October 2021 |
Source | Beijing Tiantan Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In order to bridge the great gaps, Chinese Stroke Association (CSA) and American Heart Association (AHA) sought to develop, conduct, and assess a multifaceted quality improvement intervention to increase the adherent rate of IV tPA and ET and improve 3-month clinical outcomes for these patients through our cluster-randomized stepped-wedge IMPROVE: Stroke in China trial.
Status | Completed |
Enrollment | 15895 |
Est. completion date | October 31, 2020 |
Est. primary completion date | July 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Hospitals: 1. Voluntary. 2. Hospitals from CSCA. 3. Secondary or tertiary public hospitals with an emergency department and neurologic wards that receive patients with AIS. 4. Have a 24*7 on-call stroke team. 5. Have the capacity of IV rt-PA thrombolytic therapy or/and endovascular treatment. 6. Implement at least 10 patients' rt-PA or/and endovascular treatment during the last year. 7. Admit at least 5 patients of acute ischemic stroke within 24 hours after onset each month. 8. Have full desire to improve the procedure of treatment of acute ischemic stroke. 9. Have good cooperation among Neurology department, Emergency department, Interventional department, Neurosurgery department, Laboratory and Radiology department. Patients: Patients who are =18 years old were eligible for inclusion if they presented with acute ischemic stroke diagnosed by CT and/or MRI and arrived at hospital within 6 hours after symptom onset. Exclusion Criteria: Hospitals: 1. Hospitals that can not comply with the protocol and finish the research. 2. Grade-one hospitals and non cerebral vascular disease specialized hospitals. 3. Hospitals involved in other stroke care quality improvement projects or relevant clinical trials. Patients: 1)Patients refuse to participate in this study |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantan Hospital, Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Tiantan Hospital | American Heart Association |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The adherence rate of guidelines for IV-tPA and/or endovascular treatment in eligible patients. | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | ||
Secondary | proportional change of intravenous thrombolytic therapy in eligible patients 4.5h after the onset | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | ||
Secondary | proportional change of endovascular treatment in eligible patients 6h after the onset | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | ||
Secondary | time from arrival to hospitals to intravenous thrombolytic therapy | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | ||
Secondary | door-to-puncture time | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | ||
Secondary | in-hospital mortality | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | ||
Secondary | 3-month disability(mRS=3 ) | patients will be followed up at 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 | |
Not yet recruiting |
NCT01923818 -
Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
|
Phase 2/Phase 3 |